Recommended Alerts

Sign Up For Alerts

DOJ Complaint Names Private Equity Firm as Defendant in False Claims Act Case Targeting Health Care Portfolio Company

The U.S. Department of Justice’s recent decision to name a private equity firm as a defendant in a False Claims Act complaint against one of the firm’s portfolio companies, while uncommon, shines a spotlight on potential risk areas for private equity firms whose portfolio companies operate in industries with significant False Claims Act exposure like health care. In its complaint in intervention in United States ex rel. Medrano v. Diabetic Care Rx, LLC d/b/a Patient Care America et al. (S.D. Fla. No. 15-62617-civ), filed on February 16, 2018, DOJ alleges that compounding pharmacy Patient Care America (“PCA”) paid illegal kickbacks to several marketing firms in exchange for referrals for certain compound drugs that were reimbursed by Tricare, a federal health care program that provides health insurance for current military personnel, military retirees, and their dependents. The complaint further alleges that the pharmacy’s controlling stakeholder, private equity firm Riordan, Lewis & Haden, Inc. (“RLH”), managed and controlled PCA and participated in the charged misconduct. The government’s intervention to target both PCA and its private equity shareholder reflects a potential sea change in its approach to such cases.

Read More

First Circuit Limits Inference of Pretext for FCA Retaliation Claims

Time to Read: 3 minutes Practices: False Claims Act

Printer-Friendly Version

On February 22, 2016, the First Circuit affirmed a grant of summary judgment for pharmaceutical maker GlaxoSmithKline (“GSK”) on a False Claims Act retaliation claim by a former employee. In United States ex rel. Hamrick v. GlaxoSmithKline LLC, 814 F.3d 10 (1st Cir. 2016), the court held that the employee had failed to create a jury question on whether GSK’s proffered reasons for terminating him were pretextual. The court’s decision refused to credit a series of implausible theories advanced by the employee, and placed an important limit on the principle that pretext can be inferred based on the temporal proximity of protected conduct and termination.


Relator Blair Hamrick (“Hamrick”) worked for GSK as a senior executive sales representative. In 2002, GSK Compliance interviewed Hamrick in connection with off-label marketing allegations raised by another GSK employee, Gregory Thorpe. Hamrick corroborated the allegations, and he and Thorpe subsequently filed a qui tam action against GSK.

At the same time, Hamrick’s personal and professional life began to fall apart. Over the next several months, Hamrick engaged in a range of angry, irrational behaviors, including repeated violent threats against coworkers. GSK initiated severance discussions, but when Hamrick refused to engage in the process, he was eventually terminated. After his firing, Hamrick amended his FCA complaint to add a retaliation claim under 31 U.S.C. § 3730(h). The district court granted summary judgment to GSK on this claim.

First Circuit Decision

On appeal, Hamrick conceded that GSK had satisfied its burden of advancing a non-retaliatory motive for terminating him. He contended, however, that GSK’s explanation was pretextual, and that the district court had erred in finding no genuine question of material fact on this issue when it granted summary judgment to GSK. The First Circuit affirmed.

The court’s decision patiently debunked a series of increasingly far-fetched narratives advanced by Hamrick. For example, the court gave no credence to Hamrick’s contention that GSK’s delay in firing him showed that it did not find his behavior objectionable, and it rejected out of hand his theory that the company had sent him to a conference hoping that he would have an outburst there.

More significant, the court also rejected Hamrick’s argument that a retaliatory inference could be drawn from the temporal proximity between GSK’s identification of Hamrick as a whistleblower and its decision to fire him. The court explained that while this inference might be justified in some cases – as in its earlier decision in Harrington v. Aggregate Indus.-Northeast Region, Inc., 668 F.3d 25, 33 (1st Cir. 2012) – it was not warranted here, where Hamrick’s actions had already placed him well along the road to termination by the time this identification allegedly occurred.

Ultimately, the First Circuit held, none of Hamrick’s counter-narratives created a jury question in the face of the evidence supporting GSK’s proffered motive – that Hamrick’s unhinged behavior made him a danger to himself and others. As the court observed, “No reasonable jury could in this case be swayed by Hamrick’s largely speculative attempts to dislodge GSK’s asserted motivation from its grounding in record evidence.” Hamrick, 814 F.3d at 23.


While the facts in Hamrick are rare, the decision nevertheless places broadly applicable limits on relators’ ability to reach a jury on retaliation claims. The First Circuit makes clear that, where the defendant has advanced substantial evidence of poor performance, a relator must provide more than speculation to avoid summary judgment. The decision should prove particularly useful to defendants in countering a frequent argument by relators: that the close temporal proximity between alleged protected conduct and their termination raises an inference of pretext. This inference may be justified in some cases, but as Hamrick clarifies, it is not boundless.

If you have any questions or would like to discuss the foregoing or any related matter, please contact the Ropes & Gray attorney with whom you regularly work, or an attorney in our False Claims Act practice.

Printer-Friendly Version

Cookie Settings